drugset / Trial / NCT02500901
Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)
Phase 1
Terminated
2 enrolled
Paul Mathew, MD
Hoosier Cancer Research Network · collabTesaro, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I study to determine the safety and feasibility of the combination of enzalutamide and niraparib in subjects with metastatic castration-resistant prostate cancer (CRPC).
Timeline
- Start
- 2016-03
- Primary completion
- 2016-05-10
- Completion
- 2016-05-10
Outcome
Outcome not reported
Stopped (Business): “Suspended by funder”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |
| Subject | Niraparib | Small molecule | 100 mg | — |
| Subject | Niraparib | Small molecule | 200 mg | — |
| Subject | Niraparib | Small molecule | 300 mg | — |